What did Transcarent, Inc. pay for Accolade, Inc.?

Transcarent, Inc. acquired Accolade, Inc. for $621.0M in 2025. Target revenue was approximately $467.5M. Target EBITDA was approximately $17.5M.

M&A TRANSACTION · 2025

Accolade, Inc. acquired by Transcarent, Inc.

$621.0M· Healthtech

Target

Accolade, Inc.

United States and Canada

Accolade, Inc., together with its subsidiaries, engages in the development and provision of personalized and technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based intelligent technology and multimodal support from a team of advocates and clinicians, including registered nurses, physician medical directors, pharmacists, behavioral health specialists,

Accolade, Inc. acquisition profile →

Acquirer

Transcarent, Inc.

Strategic buyer

Disclosed financials at time of acquisition

Revenue

$467.5M

EBITDA

$17.5M

Deal Value

$621.0M

What's your healthtech worth today?

12-input M&A-grade workup with sellability score, named comparable deals, and AI-written commentary. 2 minutes.

✓Sellability score with 5-driver breakdown and lift estimates
✓Named comparable M&A transactions in your sub-vertical
✓AI-written analysis grounded in your specific inputs

Run my valuation analysis →

Context

This $621.0M acquisition of Accolade, Inc. by Transcarent, Inc. sits in the healthtech sub-vertical. Run a valuation for your own healthtech business via our Healthtech valuation hub. Transcarent, Inc. is acquiring as a strategic buyer; see how strategic acquirers typically price healthtech businesses on our Healthtech strategic buyer-pool page.

Source

Data sourced from SEC Fairness Opinion - primary source. All figures reflect disclosed values at the time of the acquisition; no estimated or imputed data. Methodology

Value your own healthtech